Stock Price & Analysis

Based on the provided data and recent market activity, here's a comprehensive analysis of CSL stock:

Technical Analysis

• Current price: $337.75 (Regular market trading, +0.88%)
• The stock has entered oversold territory with RSI reading of 26.7, suggesting potential buying opportunity
• Fibonacci levels indicate:
  • Support levels: $337.39, $330.23, $318.63
  • Resistance levels: $360.58, $367.74, $379.33
  • Pivot point: $348.98

Fundamental Analysis

• Recent Performance:
  • Strong H1 FY2025 results reported on Feb 11:
    • Net profit after tax: $2.01 billion (+7% YoY)
    • CSL Behring revenue: +10% growth
    • Immunoglobulin product sales: +15% increase
  • Maintained FY2025 guidance:
    • NPATA forecast: $3.2-3.3 billion
    • Expected growth: 10-13% at constant currency
  • Increased interim dividend: $1.30 per share (+9% YoY)

Valuation Assessment

• Current intrinsic value estimate: $533 per share
• Trading at ~27% discount to fair value
• Analyst consensus price target: $472

Investment Recommendation Based on the analysis:

• Technical indicators suggest the stock is oversold and may be approaching a bottom
• Strong fundamental performance with robust plasma division growth
• Significant upside potential based on valuation metrics
• Positive analyst sentiment with Goldman Sachs maintaining Buy rating (PT: $325.40)

The current oversold conditions combined with strong fundamentals and valuation support make CSL an attractive buying opportunity at current levels.

Based on the available data and market analysis, here is the price prediction for CSL stock in 2025:

CSL's stock price is expected to reach $425-435 by end of 2025, representing a potential upside of 25-29% from current levels around $337.75. This projection is supported by:

Key Growth Drivers:

• Strong plasma division performance with CSL Behring revenue growing 10% and immunoglobulin sales up 15%
• Management guidance for 10-13% NPATA growth to $3.2-3.3 billion in FY2025
• Continued market share gains expected in influenza vaccines despite near-term challenges

Technical Analysis: The stock is currently trading near support levels around $330-337 based on Fibonacci analysis, with next resistance at $360.58. RSI at 28.69 indicates oversold conditions, suggesting potential for a technical rebound.

Analyst Views:

• Goldman Sachs maintains Buy rating with A$325.40 target
• RBC Capital has Hold rating with A$286 target
• Strong Buy consensus from Wall Street analysts with average target of $207.07

The price target factors in both fundamental growth prospects and technical support levels while accounting for current market conditions. The stock appears positioned for upside given oversold conditions and strong underlying business fundamentals.

The S1 support level for CSL Stock is $335.41 ,The R1 resistant level for CSL Stock is $358.82.

As of the end of day on 2025-02-27, the price of CSL Stock was $334.84.

The target price for CSL Stock according to analyst rating is 470.00, with the highest price target at 485.00 and the lowest at 450.00. Analysts have a Strong Buy rating on CSL Stock overall.

The market cap of CSL is $15.1B.

Based on the provided data, here's a concise analysis of CSL's valuation:

CSL shows signs of being fairly valued with some concerns. The company's P/E ratio has increased significantly from 14.46 in 2022 to 21.96 in 2023, indicating potential overvaluation compared to historical levels. The EV/EBITDA multiple has also expanded from 9.67 to 14.06, suggesting higher market expectations.

Recent financial performance reveals declining revenues (-15.8% YoY) and net income (-17% YoY), though maintaining stable margins with gross margin improving slightly to 35.63%. The stock is currently trading at $337.55, significantly below its 200-day moving average of $413.82, with RSI at 28.69 indicating oversold conditions.

According to recent DCF analysis, CSL has a fair value estimate of $533, suggesting the stock is potentially 27% undervalued at current levels. However, insider sentiment is negative with increased selling activity, while analysts maintain mixed views with price targets ranging from $286 to $325 [3, 4].

The technical indicators show bearish momentum with MACD at -12.29 and declining moving averages, suggesting near-term downside pressure remains.

Carlisle Companies Incorporated is a manufacturer and supplier of building envelope products and solutions that enable energy efficiency in buildings. The Company operates through two segments: Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT). The CCM segment produces a complete line of single-ply roofing products and warranted roof systems and accessories for the commercial building industry, including ethylene propylene diene monomer (EPDM), thermoplastic polyolefin (TPO) and polyvinyl chloride (PVC) membrane, polyiso insulation, and engineered metal roofing and wall panel systems for commercial and residential buildings. The CWT segment produces building envelope solutions that drive energy efficiency and sustainability in commercial and residential applications. Its products include waterproofing and moisture protection products, protective roofing underlayments, fully integrated liquid and sheet applied air/vapor barriers, and others.

Based on the available data and market analysis, CSL stock is projected to reach $533 by 2030, driven by strong plasma sales growth and continued market expansion. The company's robust financial performance, including a 7% profit increase and 15% jump in immunoglobulin product sales, supports this bullish outlook. Technical analysis and current market trends suggest CSL is currently undervalued by approximately 27%, indicating significant upside potential over the long term.

CSL has a total of 11000 employees.